Kogner P, Bjellerup P, Svensson T, Theodorsson E
Department of Paediatrics, Karolinska Hospital, Stockholm, Sweden.
Eur J Cancer. 1995;31A(4):557-60. doi: 10.1016/0959-8049(95)00057-p.
Neuroblastoma and its benign counterpart, ganglioneuroma, are tumours of the sympathetic nervous system, and known to produce and release various regulatory peptides. In this study, pancreastatin, a 52 amino acid regulatory peptide derived from chromogranin A, was analysed in plasma and tumour tissue from 15 children with neuroblastoma and one with ganglioneuroma. Detectable pancreastatin immunoreactivity (> 1.9 pmol/l) was found in plasma in 13 of 15 children with highest concentrations in samples from children with favourable outcome (P < 0.05). In tumour tissue, non-metastatic tumours showed higher concentrations of pancreastatin immunoreactivity (P < 0.05). However, the highest concentrations were detected in tumours from children with favourable prognosis, regardless of clinical stage at presentation (P < 0.01). Serial plasma samples from one child with neuroblastoma and one with ganglioneuroma were investigated and showed significant systemic release of pancreastatin immunoreactivity during surgical manipulation of tumours with high pancreastatin concentrations. It is concluded that pancreastatin immunoreactivity may be detected in plasma samples and tumour extracts from children with neuroblastoma and ganglioneuroma. Systemic release during surgery implied tumour origin of elevated plasma pancreastatin. Furthermore, higher pancreastatin concentrations correlate with tumour differentiation, localised clinical stage and a favourable outcome for children with these tumours. It is suggested that pancreastatin in plasma and tumour tissue may be utilised as a marker indicating favourable tumour behaviour.
神经母细胞瘤及其良性对应物神经节神经瘤是交感神经系统的肿瘤，已知会产生和释放各种调节肽。在本研究中，对15例神经母细胞瘤患儿和1例神经节神经瘤患儿的血浆和肿瘤组织中的胰抑制素（一种由嗜铬粒蛋白A衍生的含52个氨基酸的调节肽）进行了分析。15例患儿中有13例血浆中检测到可检测到的胰抑制素免疫反应性（>1.9 pmol/l），预后良好的患儿样本中浓度最高（P<0.05）。在肿瘤组织中，非转移性肿瘤显示出较高的胰抑制素免疫反应性浓度（P<0.05）。然而，无论就诊时的临床分期如何，预后良好的患儿肿瘤中检测到的浓度最高（P<0.01）。对1例神经母细胞瘤患儿和1例神经节神经瘤患儿的系列血浆样本进行了研究，结果显示，在胰抑制素浓度高的肿瘤手术操作期间，胰抑制素免疫反应性有显著的全身释放。结论是，在神经母细胞瘤和神经节神经瘤患儿的血浆样本和肿瘤提取物中可检测到胰抑制素免疫反应性。手术期间的全身释放意味着血浆中升高的胰抑制素来源于肿瘤。此外，较高的胰抑制素浓度与这些肿瘤患儿的肿瘤分化、局部临床分期和良好预后相关。建议血浆和肿瘤组织中的胰抑制素可作为指示肿瘤良好行为的标志物。
